Gide acts for ENYO Pharma on EUR40 million Series B funding round
Gide has advised ENYO Pharma on its EUR40 million Series B round of financing from US and European investors. ENYO Pharma is a clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions. This very significant funding will enable the company to finance


